Truist Financial Reaffirms “Hold” Rating for Fusion Pharmaceuticals (NASDAQ:FUSN)

Truist Financial restated their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSNFree Report) in a report released on Tuesday, Marketbeat reports. They currently have a $21.00 price objective on the stock, up from their previous price objective of $11.00.

Several other equities analysts have also issued reports on the company. Bloom Burton restated a buy rating on shares of Fusion Pharmaceuticals in a research note on Friday, January 5th. William Blair lowered Fusion Pharmaceuticals from an outperform rating to a market perform rating in a research note on Tuesday. Brookline Capital Management lowered Fusion Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday. SVB Leerink restated a market perform rating and set a $21.00 price target (up from $17.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday. Finally, Raymond James restated a market perform rating on shares of Fusion Pharmaceuticals in a research note on Tuesday. Twelve analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Fusion Pharmaceuticals presently has a consensus rating of Hold and an average price target of $20.25.

Get Our Latest Report on FUSN

Fusion Pharmaceuticals Price Performance

NASDAQ FUSN opened at $21.20 on Tuesday. Fusion Pharmaceuticals has a twelve month low of $2.31 and a twelve month high of $21.21. The company has a debt-to-equity ratio of 0.18, a quick ratio of 11.63 and a current ratio of 11.63. The stock has a market capitalization of $1.54 billion, a PE ratio of -13.01 and a beta of -0.85. The stock has a 50-day simple moving average of $11.26 and a 200 day simple moving average of $7.01.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of FUSN. Perceptive Advisors LLC acquired a new position in shares of Fusion Pharmaceuticals in the 1st quarter worth approximately $10,405,000. FMR LLC lifted its holdings in Fusion Pharmaceuticals by 73.9% during the 1st quarter. FMR LLC now owns 4,681,457 shares of the company’s stock worth $17,649,000 after buying an additional 1,989,403 shares in the last quarter. Federated Hermes Inc. lifted its holdings in Fusion Pharmaceuticals by 94.1% during the 1st quarter. Federated Hermes Inc. now owns 3,055,037 shares of the company’s stock worth $23,738,000 after buying an additional 1,481,037 shares in the last quarter. Sphera Funds Management LTD. acquired a new position in Fusion Pharmaceuticals during the 1st quarter worth $4,839,000. Finally, Wellington Management Group LLP acquired a new position in Fusion Pharmaceuticals during the 4th quarter worth $7,154,000. 72.85% of the stock is owned by institutional investors and hedge funds.

Fusion Pharmaceuticals Company Profile

(Get Free Report)

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor.

Read More

Analyst Recommendations for Fusion Pharmaceuticals (NASDAQ:FUSN)

Receive News & Ratings for Fusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.